CHAIR OF THE WEBINAR SERIES
Professor Nawab Qizilbash, MBChB MRCP (UK) BSc MSc DPhil (Oxon.)
Nawab Qizilbash is Clinical Epidemiologist & Head of OXON Epidemiology, Joint Coordinator of the ENCePP Special Interest Group on Impact of PV Activities and:
- Honorary Senior Lecturer in Epidemiology, London School of Hygiene and Tropical Medicine, London University
- Honorary Consultant Geriatrician, Hospital Cantoblanco, Madrid
- Member of Green Templeton College, Oxford University
- Co-author of x7 Lancet, x1 JAMA and x3 BMJ publications in epidemiology, pragmatic trials and meta-analysis
- Chief editor of 'Evidence-based Dementia Practice' published by Blackwells, Oxford.
Former Nawab was Director of Epidemiology and Evidence-based Medicine, GSK (1997-2005); he trained under and worked with Professor Sir Richard Peto F.R.S., and was the founding editor of the Cochrane Dementia Group. He also trained in general internal medicine and geriatrics under Professor Sir John Grimley Evans and was Honorary Consultant Physician at the Radcliffe Infirmary, Oxford (1997-2000), and St's Mary's Hospital, London (2005-2006).
Among CROs in Europe, Nawab provides clients with a unique combination of high quality epidemiological and clinical experience covering many therapeutic areas.
FRANCE WEBINAR KEYNOTE SPEAKER
March 13, 2019
Professor Nicholas Moore, MD, PhD, FRCP (Edin)
FISPE, Honorary Member ISOP, Chevalier dans l'ordre National des Palmes Académiques Nicholas Moore is Head of the department of Pharmacology in the University of Bordeaux.
Nicholas Moore was born in New York, USA. He did his medical studies in Paris then trained in cardiology and pharmacology in Rouen. He spent dozen years more in Rouen in Clinical Pharmacology and Pharmacovigilance, during which time he became vice-president of the French Association of Regional Pharmacovigilance Centres, and founded the European Society of Pharmacovigilance. He moved to Bordeaux in 1996 as Professor of Clinical Pharmacology.
Since 2003, Pr Nicholas Moore is the Director of the Department of Pharmacology of the University of Bordeaux that has over 100 members of staff and is constituted of: Clinical Pharmacology and Pharmacoepidemiology research units, Laboratories for Experimental pharmacology, Toxicology and Therapeutic Drug Monitoring as well as regional Pharmacovigilance and Pharmacodependence Centres. Pr Nicholas Moore develops fundamental and applied research projects in Phytopharmacology as a team-leader in the Experimental Pharmacology Laboratory.
Pr Nicholas Moore is involved in the advisory group of the EMEA project: "European Network of Centres of Excellence in Pharmacovigilance and Pharmacoepidemiology" (ENCePP).
He is also Head of Clinical Research of the University Hospital of Bordeaux and of the South-West France Inter-Region, member of the Hospital Board, and of the Regional Ethics Committee (DIRC, CPP SOOM3).
He is founder and President of the International Society of Pharmacovigilance (ISoP), vice-chairman of the European Association of Clinical Pharmacology and Therapeutics (EACPT), and on the board of directors of the International Society for Pharmacoepidemiology (ISPE).
He has been elected Fellow of the Royal College of Physicians of Edinburgh, Fellow of the International Society of Pharmacoepidemiology, of the Felow of Chinese Medical Association of Minorities. He is also invited professor of Pharmacology at the Medical University of Xinjiang (China) and the Institute of traditional Uyghur Medicine.
He has co-authored over 400 papers in peer-reviewed journals.
UK WEBINAR KEYNOTE SPEAKER
April 25, 2019
Professor Thomas MacDonald, BSC, MBCHB, MD
Professor of Clinical Pharmacology & Pharmacoepidemiology, University of Dundee, and Honorary Consultant Physician at Ninewells Hospital and Medical School.
His research interests are hypertension, cardiovascular disease, pharmacoepidemiology and drug safety and innovative trial designs. He is past president of the British and Irish Hypertension Society, past president of the International Society of Pharmacoepidemiology and the current director of the Tayside Medicines Monitoring Unit (MEMO Research) which has access to the MEMO database and to the CPRD database. He is an elected member of the steering committee of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).
Professor MacDonald has published extensively on drug safety especially the safety of non-steroidal anti-inflammatory drugs (NSAIDs). He has also published many studies of hypertension and other cardiovascular risk factors and cardiovascular disorders.
ITALY WEBINAR KEYNOTE SPEAKER
May 16, 2019
Professor Carlo Giaquinto, MD
Department of Paediatrics at the University of Padova,
Carlo Giaquinto is head of several organisations including, Head of the Referral Centre for Paediatric HIV infection at the Department of Paediatrics of the University of Padua since 1993, Head of the Paediatric European network treatment AIDS (PENTA network) since 1994 and co-chair of the EU funded Network of Excellence TEDDY (Task Force in Europe for Drug Development in the Young). He is also president of the PENTA foundation and chairman of the Paediatric Rotavirus European Committee (PROTECT) group. He is also the chair of the GRIP project (Global Research in Pediatrics) an EU funded network of Excellence.
Dr Giaquinto is the coordinator for various projects including the social AIDS projects financed by the European Community and by other international organisations both in Europe and Africa. He is the coordinator of Pedianet: a primary care paediatric database. He has served as an honorary senior lecturer in the centre for paediatric epidemiology and biostatistics of the Institute of Child Health in London since 2002.
He is Author of more than 180 publications in peer-reviewed journals and has been invited as speaker at more than 300 conferences and international workshops across the world.
NORDIC COUNTRIES WEBINAR KEYNOTE SPEAKER
June 5, 2019
Professor Vera Ehrenstein, MPH, DSc
Professor at the Department of Clinical Epidemiology Aarhus University, Denmark, responsible for post-marketing studies.
Vera Ehrenstein coordinates several international pharmacoepidemiology, pharmacovigilance and clinical epidemiology studies in collaboration with industry or regulators. She is a member of the ENCePP Steering Committee and serves as the 2016-2017 Chair of the Academic Council at the International Society of Pharmacoepidemiology. She earned a doctorate in epidemiology in 2008, and an MPH in epidemiology and biostatistics in 2000, from Boston University.
Vera Ehrenstein has co-authored a book chapter and published about 80 peer-reviewed papers within the fields of clinical epidemiology, pharmacoepidemiology and fetal origins of adult disease.
GERMANY WEBINAR KEYNOTE SPEAKER
July 3, 2019
Dr Niklas Schmedt, DrPH
Niklas is head of the “Health Services Research and Pharmacoepidemiology” unit at InGef – Institute for Applied Health Research Berlin and holds a Doctor of Public Health degree (2016) from the University of Bremen.
After his master’s degree in public health in 2012 at the University of Bremen, he worked as research associate at the “Drug Safety” unit of the Leibniz Institute for Prevention Research and Epidemiology – BIPS at Bremen and completed intermediate and advanced courses in Pharmacoepidemiology at McGill University in Montréal. Since 2016, he is working at the InGef – Institute for Applied Health Research in Berlin. His scientific focus is on health services research and pharmacoepidemiology based on large German claims databases.
He is vice-chair of the pharmacoepidemiology working group of the German Society of Epidemiology and member of the editorial board of GMS Medical Informatics, Biometry and Epidemiology (MIBE).
Pr Miriam Sturkenboom, PhD MPH
From 2008 till 2017 she was a professor in Observational Data Analysis at the Department of Medical Informatics of the Erasmus University Medical Center in the Netherlands. Mid 2017 she transferred to the Department of Global Health at the Julius Center at University Medical Center Utrecht in the Netherlands.
She has a PhD from the Faculty of Mathematics and Physics in Groningen (cum laude), a pharmacy degree from the same University and a Master in Epidemiology from the Harvard School of Public Health. She is a past president of the International Society for Pharmacoepidemiology. She serves as expert to EMA, FDA, WHO and many other organizations
Her research interests focus on knowledge discovery from data collected in routine health care to improve evidence on drug and vaccine safety in particular in vulnerable populations (children, pregnancy and elderly). Her research focuses on the creation of international socio-technological ecosystems that allow for big data mining, pooling and analysis to learn about the use and effects of drugs after marketing. These infrastructures have been tested and used as prototypes in many distributed networks in projects funded by the European Commission, the Innovative Medicines Initiative, the European Medicines Agency, ECDC, and also privately funded projects that she coordinates (d/s).
She is a coordinator of the ADVANCE public-private collaboration, aiming to establish a tested system for the monitoring of benefits and risks of vaccines. She is a coordinator of the IMI-funded ConcepTION project, building an ecosystem to assess drugs safety in pregnancy and lactation. In terms of quantitative research outputs: she supervises/d more than 50 PhD students, has more than 400 peer-reviewed papers in the area of pharmacovigilance, pharmacoepidemiology and medical informatics and an h-index of 72.
JAPAN WEBINAR KEYNOTE SPEAKER
October 2019 (date TBD)
Professor Masao Iwagami, MD, MPH, MSc, PhD
Masao Iwagami is a Clinical Epidemiologist and Assistant Professor in the Department of Health Services Research, University of Tsukuba, Japan. He graduated from the University of Tokyo in 2008, completed his internship and residency in Japanese hospitals, and worked as a Research Assistant Professor in the Department of Hemodialysis and Apheresis, the University of Tokyo Hospital in 2013.
He formally studied clinical epidemiology and pharmacoepidemiology at the School of Public Health, the University of Tokyo in 2012, at MSc Epidemiology in 2013/2014, Pharmacoepidemiology and Pharmacovigilance short course in 2017/2018, and PhD Epidemiology and Population Health in 2014-2018 at London School of Hygiene & Tropical Medicine.
He is well experienced in conducting medical research using large databases of routinely collected data, such as UK Clinical Practice Research Datalink (CPRD), Japanese Diagnosis Procedure Combination (DPC) Database, Medical Data Vision (MDV) Database, and Japan Medical Data Center Database (JMDC).
TAIWAN WEBINAR KEYNOTE SPEAKER
October 2019 (date TBD)
Professor Yea-Huei Kao Yan
Dr Yea-Huei Kao Yang is affiliated to National Cheng Kung University. Dr Yea-Huei Kao Yang is currently providing services as J186.
Dr Yea-Huei Kao Yang has authored and co-authored multiple peer-reviewed scientific papers and presented works at many national and international conferences. Her contributions have acclaimed recognition from honourable subject experts around the world.
Dr Yea-Huei Kao Yang is actively associated with different societies and academies. Dr Yea-Huei Kao Yang academic career is decorated with several reputed awards and funding. Her research interests include Clinical Pharmacy and Pharmacoepidemiology.
SOUTH KOREA WEBINAR KEYNOTE SPEAKER
November 2019 (date TBD)
Dr Ju-Young Shin
Ju-Young Shin is a current assistant professor at school of pharmacy, SungKyunKwan University (SKKU). She also serves as an associate editor of Pharmacoepidemiology and Drug Safety (PDS). She received her B.S. in pharmacy from Seoul National University, MPH in health policy and PhD in pharmacoepidemiology from the Seoul National University College of Medicine. She was a visiting fellow at the University of South Australia, and postdoctoral fellow at McGill University.
She published more than 90 peer-reviewed journals and published her study in the British Medical Journal (BMJ), twice, regarding the safety of antidepressants and ADHD medication using 50 million Korean healthcare databases. Her area of research is the safety of psychotropic drugs, vaccine safety, methodology development, and drug utilization review in the frail population. She is leading or co-leading several projects sponsored by Korea Ministry of Food and Drug Safety, Ministry of Health and Welfare, Center for Disease Control and Prevention, National Research Foundations, and Pharmaceutical companies.
She was a past-team director at Korea Institute of Drug Safety and Risk Management (KIDS) and led several epidemiological studies. She is now in charge of vice-director in one of Korean regional pharmacovigilance centre- pharmacist association. She also serves as a consultant for several Korean governmental committees including national evidence-based collaborating Agency (NECA), and KIDS. She has been a member of International Society for Pharmacoepidemiology (ISPE) since 2007 and is currently a member of the board of directors of Korea society of Pharmacoepidemiology and Risk Management (KoPERM), Korea society of epidemiology, and Korea academy of social and managed care pharmacy.
RISK MINIMISATION STUDIES WEBINAR KEYNOTE SPEAKER
June 2020 (date TBD)
Pr Marie Louise De Bruin, PharmD MSc PhD
Marie Louise (Marieke) De Bruin is professor in Regulatory Science at the Faculty of Health and Medical Sciences of the University of Copenhagen, Director of the Copenhagen Centre for Regulatory Science (CORS) at the Department of Pharmacy and Ex-PRAC member, EMA (2012 – 2018)
Her research focusses on developing new tools, standards and approaches to evaluate the efficacy, safety, quality and performance of medical products in order to assess benefit-risk and facilitate a sound and transparent regulatory decision making.
The Copenhagen Centre for Regulatory Science (CORS) aims at being the international partner for academic leadership in regulatory science, research and education and to participate in building the regulatory framework that will make innovative medicinal products available to patients.
Marie Louise (Marieke) De Bruin was trained as a pharmacist (Utrecht University) and epidemiologist (Erasmus University Rotterdam) and has combined academic research with working for the regulatory authorities, both nationally (Pharmacovigilance expert for the Dutch Medicines Evaluation Board 2008-2016) and internationally (European Commission appointed independent Scientific Expert of the Pharmacovigilance Risk Assessment Committee (PRAC), at the European Medicines Agency 2012-2018). She has a strong background in epidemiology, is member of the steering group of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP 2017-2019) and has applied quantitative methods from epidemiology to study regulatory science research questions. Working as a regulator has given her theoretical training about and hands-on experience in the functioning of the regulatory system. She has wide experience in coordination and execution of public-private as well as academic research collaborations, nationally, at EU level and globally.
Her personal motivation to engage in this field of research is to benefit public health and originates from her training as a health care professional. With her research, she wants to improve the drug regulatory system, by systematically studying its structure and behaviour as well as designing new tools to facilitate regulatory decision-making. Through the improvement of the drug regulatory system, she aims to contribute to the improvement of the health of society.